Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo

International Journal of Oncology

Volumn 30, Issue 6, 2007, Pages 1413-1425

  Issat, Tadeusz ^a   Nowis, Dominika ^a   Legat, Magdalena ^a   Makowski, Marcin ^a   Klejman, Marcin P ^b   Urbanski, Jakub ^b   Skierski, Janusz ^c   Koronkiewicz, Miroslawa ^c   Stoklosa, Tomasz ^a   Brzezinska, Agnieszka ^d   Bil, Jacek ^a   Gietka, Jan ^a   Jakóbisiak, Marek ^a   Golab, Jakub ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^c NATIONAL MEDICINES INSTITUTE   (Poland)

^d NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

Antitumor; Bisphosphonates; Cancer; Cytostatic cytotoxic effects; Statins

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PAMIDRONIC ACID;

ADENOCARCINOMA; ANIMAL; ARTICLE; CELL ADHESION; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; IN VITRO STUDY; MOUSE; PANCREAS TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DIPHOSPHONATES; DRUG SYNERGISM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MICE; PANCREATIC NEOPLASMS;

EID: 34447282251     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.6.1413     Document Type: Article

References (66)

1. Tobert JA: Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2: 517-526, 2003. (Pubitemid 37361744)
2. Jakobisiak M, Bruno S, Skierski JS and Darzynkiewicz Z: Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 88: 3628-3632, 1991.
3. Keyomarsi K, Sandoval L, Band V and Pardee AB: Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51: 3602-3609, 1991.
4. Giermasz A, Makowski M, Kozlowska E, Nowis D, Maj M, Jalili A, Feleszko W, Wojcik C, Dabrowska A, Jakobisiak M and Golab J: Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. Int J Cancer 97: 746-750, 2002.
5. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS and Gomez DE: Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50: 83-93, 1998.
6. Matar P, Rozados VR, Binda MM, Roggero EA, Bonfil RD and Scharovsky OG: Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma. Clin Exp Metastasis 17: 19-25, 1999.
7. Soma MR, Baetta R, De Renzis MR, Mazzini G, Davegna C, Magrassi L, Butti G, Pezzotta S, Paoletti R and Fumagalli R: In vivo enhanced antitumor activity of carmustine [N,N′-bis(2-chloroethyl)-N-nitrosourea] by simvastatin. Cancer Res 55: 597-602, 1995.
8. Jani JP, Specht S, Stemmler N, Blanock K, Singh SV, Gupta V and Katoh A: Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion Metastasis 13: 314-324, 1993.
9. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y and Matsuzawa Y: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84: 886-891, 2001.
10. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E and Myers CE: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2: 483-491, 1996.
11. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ and Guchelaar HJ: The risk of cancer in users of statins. J Clin Oncol 22: 2388-2394, 2004.
12. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK and Rennert G: Statins and the risk of colorectal cancer. N Engl J Med 352: 2184-2192, 2005.
13. Kaye JA and Jick H: Statin use and cancer risk in the General Practice Research Database. Br J Cancer 90: 635-637, 2004. (Pubitemid 38297203)
14. Bonovas S, Filioussi K, Tsavaris N and Sitaras NM: Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23: 8606-8612, 2005.
15. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG and Shapiro S: Statin use and the risk of breast and prostate cancer. Epidemiology 13: 262-267, 2002. (Pubitemid 34415845)
16. Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, Onori N, Scarpa S and Tonini G: The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14: 1468-1476, 2003.
17. Coleman RE: Bisphosphonates: clinical experience. Oncologist 9 (suppl 4): 14-27, 2004.
18. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J and Knight RD: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488-493, 1996.
19. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J and Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335: 1785-1791, 1996.
20. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M and Reitsma DJ: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17: 846-854, 1999.
21. Fleisch H: Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42: 919-944, 1991.
22. Berenson JR: Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol 29: 12-18, 2002.
23. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH and Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296: 235-242, 2001.
24. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G and Rogers MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581-589, 1998.
25. Clezardin P, Ebetino FH and Fournier PG: Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 65: 4971-4974, 2005. (Pubitemid 40827299)
26. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS and Vessella RL: Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9: 295-306, 2003.
27. Hiraga T, Williams PJ, Ueda A, Tamura D and Yoneda T: Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10: 4559-4567, 2004.
28. Smith MR: Antitumor activity of bisphosphonates. Clin Cancer Res 9: 5433-5434, 2003.
29. Santini D, Vincenzi B, Tonini G, Scarpa S and Baldi A: Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9: 3215; author reply 3216, 2003.
30. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V and Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302: 1055-1061, 2002.
31. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M and Tonini G: Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9: 2893-2897, 2003.
32. Yamagishi S, Abe R, Inagaki Y, Nakamura K, Sugawara H, Inokuma D, Nakamura H, Shimizu T, Takeuchi M, Yoshimura A, Bucala R, Shimizu H and Imaizumi T: Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 165: 1865-1874, 2004.
33. Coleman RE: Bisphosphonates in breast cancer. Ann Oncol 16: 687-695, 2005.
34. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y and Takashima S: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23: 3314-3321, 2005.
35. Yano S, Zhang H, Hanibuchi M, Miki T, Goto H, Uehara H and Sone S: Combined therapy with a new bisphosphonate, minodronate (YM529) and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice. Clin Cancer Res 9: 5380-5385, 2003. (Pubitemid 37413593)
36. Inoue K, Karashima T, Fukata S, Nomura A, Kawada C, Kurabayashi A, Furihata M, Ohtsuki Y and Shuin T: Effect of combination therapy with a novel bisphosphonate, minodronate (YM529) and docetaxel on a model of bone metastasis by human transitional cell carcinoma. Clin Cancer Res 11: 6669-6677, 2005.
37. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE and Holen I: Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113: 364-371, 2005. (Pubitemid 40038702)
38. Algur E, Macklis RM and Hafeli UO: Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. Int J Radiat Oncol Biol Phys 61: 535-542, 2005. (Pubitemid 40164451)
39. Journe F, Chaboteaux C, Magne N, Duvillier H, Laurent G and Body JJ: Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. Breast Cancer Res 8: R2, 2005. (Pubitemid 44644837)
40. Feleszko W, Zagozdzon R, Golab J and Jakobisiak M: Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. Eur J Cancer 34: 406-411, 1998.
41. Golab J, Stoklosa T, Zagozdzon R, Kaca A, Giermasz A, Pojda Z, Machaj E, Dabrowska A, Feleszko W, Lasek W, Iwan-Osiecka A and Jakobisiak M: G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its anti-tumor activity in a melanoma model in mice. Ann Oncol 9: 63-69, 1998.
42. Nowis D, Legat M, Grzela T, Niderla J, Wilczek E, Wilczynski GM, Glodkowska E, Mrowka P, Issat T, Dulak J, Jozkowicz A, Was H, Adamek M, Wrzosek A, Nazarewski S, Makowski M, Stoklosa T, Jakobisiak M and Golab J: Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene 25: 3365-3374, 2006.
43. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
44. Jakobisiak M and Golab J: Potential antitumor effects of statins (Review). Int J Oncol 23: 1055-1069, 2003.
45. Kozar K, Kaminski R, Legat M, Kopec M, Nowis D, Skierski JS, Koronkiewicz M, Jakobisiak M and Golab J: Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int J Oncol 24: 1149-1157, 2004.
46. Kozar K, Kaminski R, Switaj T, Oldak T, Machaj E, Wysocki PJ, Mackiewicz A, Lasek W, Jakobisiak M and Golab J: Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2′-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clin Cancer Res 9: 3124-3133, 2003.
47. Holstein SA, Knapp HR, Clamon GH, Murry DJ and Hohl RJ: Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 57: 155-164, 2006.
48. Budman DR and Calabro A: Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology 70: 147-153, 2006.
49. Katz MS: Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol 2: 82-89, 2005. (Pubitemid 40790141)
50. Waters D: Statins and safety: applying the results of randomized trials to clinical practice. Am J Cardiol 92: 692-695, 2003.
51. Ohtsuka Y, Manabe A, Kawasaki H, Hasegawa D, Zaike Y, Watanabe S, Tanizawa T, Nakahata T and Tsuji K: RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro. Blood 106: 3134-3141, 2005.
52. Gordon S, Helfrich MH, Sati HI, Greaves M, Ralston SH, Culligan DJ, Soutar RL and Rogers MJ: Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br J Haematol 119: 475-483, 2002.
53. Wada A, Fukui K, Sawai Y, Imanaka K, Kiso S, Tamura S, Shimomura I and Hayashi N: Pamidronate induced antiproliferative, apoptotic and anti-migratory effects in hepatocellular carcinoma. J Hepatol 44: 142-150, 2006. (Pubitemid 41772528)
54. Lee J, Lee I, Park C and Kang WK: Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells. Biochem Biophys Res Commun 339: 748-754, 2006.
55. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD and Penn LZ: Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 15: 1398-1407, 2001.
56. Tanaka T, Tatsuno I, Uchida D, Moroo I, Morio H, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, Saito Y and Hirai A: Geranylgeranyl-pyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition. J Neurosci 20: 2852-2859, 2000.
57. Caraglia M, D'Alessandro AM, Marra M, Giuberti G, Vitale G, Viscomi C, Colao A, Prete SD, Tagliaferri P, Tassone P, Budillon A, Venuta S and Abbruzzese A: The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene 23: 6900-6913, 2004.
58. Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, De Solms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC and Kohl NE: Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res 61: 8758-8768, 2001.
59. Morgan MA, Sebil T, Aydilek E, Peest D, Ganser A and Reuter CW: Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. Br J Haematol 130: 912-925, 2005. (Pubitemid 43899732)
60. Morgan MA, Wegner J, Aydilek E, Ganser A and Reuter CW: Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors. Leukemia 17: 1508-1520, 2003.
61. Kagawa S, Gu J, Honda T, McDonnell TJ, Swisher SG, Roth JA and Fang B: Deficiency of caspase-3 in MCF7 cells blocks Bax-mediated nuclear fragmentation but not cell death. Clin Cancer Res 7: 1474-1480, 2001.
62. Giraudo E, Inoue M and Hanahan D: An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114: 623-633, 2004. (Pubitemid 39578752)
63. Leppa S, Saarto T, Vehmanen L, Blomqvist C and Elomaa I: Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer. Breast Cancer Res Treat 90: 117-125, 2005.
64. Thunyakitpisal PD and Chaisuparat R: Simvastatin, an HMGCoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci 94: 403-409, 2004.
65. Denoyelle C, Albanese P, Uzan G, Hong L, Vannier JP, Soria J and Soria C: Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal 15: 327-338, 2003.
66. Hewitt RE, Lissina A, Green AE, Slay ES, Price DA and Sewell AK: The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139: 101-111, 2005. (Pubitemid 40066134)